Clinical trial
S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in…
NCT00075764 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00075764 |
|---|---|
| Title | S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer |
| Official title | Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH NCIC Clinical Trials Group |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | anastrozole, fulvestrant |
| Enrollment | 695 |
| Start date | Apr 1, 2004 |
| Primary completion | Dec 1, 2012 |
| Completion | Oct 1, 2018 |
| First posted | Jan 13, 2004 |
| Last update posted | Jan 13, 2021 |
| Countries | Canada, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: